
In this subway-themed activity, Roy M. Fleischmann, MD, discusses the latest evidence for the management of patients with moderate-to-severe rheumatoid arthritis who do not achieve treatment goals with initial disease-modifying anti-rheumatic drug therapy. A key treatment principle emphasized by Dr. Fleischmann is using a treat-to-target approach guided by validated tools for assessing disease activity and patient-reported outcomes. Among the treatment options, Dr. Fleischmann highlights the pharmacology of the latest approved treatments for rheumatoid arthritis. Using case scenarios, he illustrates how they might be integrated with other therapies.
Course Credit:
1.00 AMA PRA Category 1 CreditTM
Dates:
Opens: 2020-10-16
Closes: 2021-10-15
Target Audience:
This activity was developed for a national audience of rheumatologists, primary care physicians, nurse practitioners, physician assistants and other healthcare providers who manage patients with rheumatoid arthritis.
This activity is supported by an independent educational grant from Sanofi Genzyme.
-
Roy M. Fleischmann, MD
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Medical Director
Metroplex Clinical Research Center
Dallas, Texas
Learning Objectives
- Describe the clinical pharmacology, safety and efficacy of the latest approved treatments for rheumatoid arthritis (RA)
- Incorporate bDMARDs and tsDMARDs into management of patients with moderate-to-severe RA based on their individual needs, best evidence, and treatment guidelines
- Use a treat-to-target approach guided by validated tools for assessing disease activity and patient-reported outcomes
- Select evidence-based therapy options including combination therapy when RA treatment goals are not achieved with initial DMARD therapy
- Identify extra-articular manifestations in a patient with RA through collaboration with the primary care provider
Faculty Disclosures
Roy M. Fleischmann, MD
Consultant: AbbVie, Amgen, Eli Lilly, GSK, Pfizer, UCB
Research Support: AbbVie, Amgen, BMS, Eli Lilly, GSK, Pfizer, Sanofi, TEVA, UCB
Accreditation and Certification
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Additional Content Planners
Eugene Cullen, MD (Peer Reviewer)No significant relationship to disclose
Heather M. Jimenez, FNP-C (Nurse Planner)
No significant relationships to disclose.
Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
All members of the Eisenhower Health Education Committee have no relevant commercial relationships to disclose.